# DORADO-EX: Long-Term Safety Extension Study to the Phase 3 DORADO Study (Protocol DAR-311) of Darusentan in Resistant Hypertension

> **NCT00353574** · PHASE3 · TERMINATED · sponsor: **Gilead Sciences** · enrollment: 282 (actual)

## Conditions studied

- Hypertension

## Interventions

- **DRUG:** Darusentan

## Key facts

- **NCT ID:** NCT00353574
- **Lead sponsor:** Gilead Sciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2006-09
- **Primary completion:** 2010-02
- **Final completion:** 2010-04
- **Target enrollment:** 282 (ACTUAL)
- **Why stopped:** Study DAR-312 did not meet primary co-endpoints
- **Last updated:** 2014-03-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00353574

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00353574, "DORADO-EX: Long-Term Safety Extension Study to the Phase 3 DORADO Study (Protocol DAR-311) of Darusentan in Resistant Hypertension". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT00353574. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*